OpenEvidence, the 'ChatGPT for doctors,' doubles valuation to $12 billion
Why it matters
OpenEvidence, a Massachusetts-based healthcare technology company, has doubled its valuation to $12 billion following a funding round led by Thrive and DST.
Article tone
Neutral
How the article is written, as reported by the source.
Expected market reaction
Market impact analysis based on bullish sentiment with 90% confidence.
Evidence trail
Evidence
Source
CNBC
Claim
OpenEvidence, the 'ChatGPT for doctors,' doubles valuation to $12 billion
AI inference
Bullish · 90%
Generated
2026-01-21 12:30
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 35269
Original source
OpenEvidence, based in Massachusetts, has topped a $12 billion valuation in a funding round led by Thrive and DST.
Original article published by CNBC on January 21, 2026. Analysis and insights provided by AnalystMarkets AI.